mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
3e-11 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
5e-10 |
mRNA |
Cerulenin |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
1e-09 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
1e-09 |
mRNA |
PX-12 |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
2e-09 |
mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
2e-09 |
mRNA |
LY-2183240 |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
4e-09 |
mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
6e-09 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
7e-09 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
2e-08 |